Cargando…

Does the Time of Day at Which Endocrine Therapy Is Taken Affect Breast Cancer Patient Outcomes?

Background: Non-compliance and non-persistence with endocrine therapy for breast cancer is common and usually related to treatment-induced side effects. There are anecdotal reports that simply changing the time of day when taking endocrine therapy (i.e., changing morning dosing to evening dosing or...

Descripción completa

Detalles Bibliográficos
Autores principales: Beltran-Bless, Ana-Alicia, Vandermeer, Lisa, Ibrahim, Mohammed F. K., Hutton, Brian, Shorr, Risa, Savard, Marie-France, Clemons, Mark
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8293101/
https://www.ncbi.nlm.nih.gov/pubmed/34287262
http://dx.doi.org/10.3390/curroncol28040229
_version_ 1783724957189013504
author Beltran-Bless, Ana-Alicia
Vandermeer, Lisa
Ibrahim, Mohammed F. K.
Hutton, Brian
Shorr, Risa
Savard, Marie-France
Clemons, Mark
author_facet Beltran-Bless, Ana-Alicia
Vandermeer, Lisa
Ibrahim, Mohammed F. K.
Hutton, Brian
Shorr, Risa
Savard, Marie-France
Clemons, Mark
author_sort Beltran-Bless, Ana-Alicia
collection PubMed
description Background: Non-compliance and non-persistence with endocrine therapy for breast cancer is common and usually related to treatment-induced side effects. There are anecdotal reports that simply changing the time of day when taking endocrine therapy (i.e., changing morning dosing to evening dosing or vice versa) can reduce side effects. Literature review: We conducted a literature review to evaluate whether changing the timing of tamoxifen and/or aromatase inhibitor administration impacted patient outcomes. No randomized control trials or prospective cohort studies that looked at time of day of endocrine therapy were identified through our review of literature from 1947 until August 2020. Conclusions: Given the rates of endocrine therapy non-compliance and non-persistence reported in the literature, ranging from 41–72% and 31–73%, respectively, simply changing the time of day when medications are taken could be an important strategy. We could identify no trials evaluating the effect of changes in timing of administration of endocrine therapy on breast cancer patient outcomes. Randomized control trials are clearly indicated for this simple and cost-effective intervention.
format Online
Article
Text
id pubmed-8293101
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-82931012021-07-22 Does the Time of Day at Which Endocrine Therapy Is Taken Affect Breast Cancer Patient Outcomes? Beltran-Bless, Ana-Alicia Vandermeer, Lisa Ibrahim, Mohammed F. K. Hutton, Brian Shorr, Risa Savard, Marie-France Clemons, Mark Curr Oncol Opinion Background: Non-compliance and non-persistence with endocrine therapy for breast cancer is common and usually related to treatment-induced side effects. There are anecdotal reports that simply changing the time of day when taking endocrine therapy (i.e., changing morning dosing to evening dosing or vice versa) can reduce side effects. Literature review: We conducted a literature review to evaluate whether changing the timing of tamoxifen and/or aromatase inhibitor administration impacted patient outcomes. No randomized control trials or prospective cohort studies that looked at time of day of endocrine therapy were identified through our review of literature from 1947 until August 2020. Conclusions: Given the rates of endocrine therapy non-compliance and non-persistence reported in the literature, ranging from 41–72% and 31–73%, respectively, simply changing the time of day when medications are taken could be an important strategy. We could identify no trials evaluating the effect of changes in timing of administration of endocrine therapy on breast cancer patient outcomes. Randomized control trials are clearly indicated for this simple and cost-effective intervention. MDPI 2021-07-06 /pmc/articles/PMC8293101/ /pubmed/34287262 http://dx.doi.org/10.3390/curroncol28040229 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Opinion
Beltran-Bless, Ana-Alicia
Vandermeer, Lisa
Ibrahim, Mohammed F. K.
Hutton, Brian
Shorr, Risa
Savard, Marie-France
Clemons, Mark
Does the Time of Day at Which Endocrine Therapy Is Taken Affect Breast Cancer Patient Outcomes?
title Does the Time of Day at Which Endocrine Therapy Is Taken Affect Breast Cancer Patient Outcomes?
title_full Does the Time of Day at Which Endocrine Therapy Is Taken Affect Breast Cancer Patient Outcomes?
title_fullStr Does the Time of Day at Which Endocrine Therapy Is Taken Affect Breast Cancer Patient Outcomes?
title_full_unstemmed Does the Time of Day at Which Endocrine Therapy Is Taken Affect Breast Cancer Patient Outcomes?
title_short Does the Time of Day at Which Endocrine Therapy Is Taken Affect Breast Cancer Patient Outcomes?
title_sort does the time of day at which endocrine therapy is taken affect breast cancer patient outcomes?
topic Opinion
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8293101/
https://www.ncbi.nlm.nih.gov/pubmed/34287262
http://dx.doi.org/10.3390/curroncol28040229
work_keys_str_mv AT beltranblessanaalicia doesthetimeofdayatwhichendocrinetherapyistakenaffectbreastcancerpatientoutcomes
AT vandermeerlisa doesthetimeofdayatwhichendocrinetherapyistakenaffectbreastcancerpatientoutcomes
AT ibrahimmohammedfk doesthetimeofdayatwhichendocrinetherapyistakenaffectbreastcancerpatientoutcomes
AT huttonbrian doesthetimeofdayatwhichendocrinetherapyistakenaffectbreastcancerpatientoutcomes
AT shorrrisa doesthetimeofdayatwhichendocrinetherapyistakenaffectbreastcancerpatientoutcomes
AT savardmariefrance doesthetimeofdayatwhichendocrinetherapyistakenaffectbreastcancerpatientoutcomes
AT clemonsmark doesthetimeofdayatwhichendocrinetherapyistakenaffectbreastcancerpatientoutcomes